Press release

Q3 Wrap-up: A Successful Year to Date for Adents in the Competitive Pharma Traceability Market

Market share gain, innovative Blockchain-based traceability platform and advancements in supply chain data-sharing solutions highlight 2018 achievements.

Adents, a leading serialization and track & trace solutions provider announced several notable accomplishments at the end of Q3. As a direct result of this, the company reported a 280% increase in the EMEA, along with an impressive 350% increase in North America. Key milestones include:

  • Adents gained market share by winning more than 50 business competitions and gaining new Big Pharma customers.
  • Our pharmaceuticals customers (CMO, Big Pharma Companies) agreed to deploy more than 300 Adents Prodigi connectors that can be linked to all main Level-4 solutions of the market.
  • Adents is very well positioned regarding the Verification Router Service (VRS) project development for the US market. The company is very active in the Healthcare Distribution Alliance (HDA) working group, which is also leading the VRS specifications program. Four of the five top wholesalers in the US market are currently testing Adents’ VRS solution.
  • Adents has introduced Adents DispaX, a new mobile application developed for pharmaceutical warehouses, wholesalers, distributors and dispensers (such as pharmacies and hospitals) for improved traceability throughout the supply chain.
  • Adents collaborated with Microsoft to develop and release Adents NovaTrack, a high-end blockchain-based track and trace platform which was designed to easily provide a standard solution to secure and analyze transactions among any local or global supply chain.
  • Furthering its position as market leader, Adents recently collaborated with Pharma key players to launch the Adents Serialization Innovation Summits, which were held in both Europe and the US.
  • Adents continues to solidify its relationships with its main technology partners Siemens and Microsoft with a deeper technical integration and new business development approach.

“I am thrilled to share Adents’ Q3 performance. We’ve exceeded our objectives for both  new customers and product launches, capped by the release of our Blockchain-based Track and Trace Platform, Adents NovaTrack,” said Christophe Devins, CEO and Founder.

“We want our customers to have access to an Adents solution wherever they are and have made strides to increase our customer portfolio within our major markets,” continued Devins.

Silvain Vernet


COVID-19: Adents' Business Continuity plan
The COVID-19 coronavirus epidemic has already affected thousands of people around the world and we expect the French government to announce stricter containment measures soon. Since Adents employees are mainly based in France and the United States, we take the health and economic risks linked to this epidemic very seriously.
Laboratoires Théa addresses European FMD and South Korea market regulation requirements with Adents Cloud serialization solution
Leading Ophtalmic Pharmaceuticals Company chose Adents Prodigi to connect with approximately 15 supply chain partners to stay compliant with current and future regulations.
Pharmascience Chooses Software from Adents to Ensure European FMD and US DSCSA Serialization Compliance Regulations
Pharmascience,the 4th largest manufacturer of over-the-counter and generic drugs in Canada, has chosen to partner with Adents, a leading provider of versatile and easily deployable serialization and track-and-trace software solutions, to assure compliance with the European Falsified Medicines Directive as well as the U.S. DSCSA serialization regulation.